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Abstract: Plasma concentrations of metabolites along the choline oxidation pathway have been linked
to increased risk of major lifestyle diseases, and peroxisome proliferator-activated receptors (PPARs)
have been suggested to be involved in the regulation of key enzymes along this pathway. In this study,
we investigated the effect of PPAR activation on circulating and urinary one-carbon metabolites
as well as markers of B-vitamin status. Male Wistar rats (n = 20) received for 50 weeks either a
high-fat control diet or a high-fat diet with tetradecylthioacetic acid (TTA), a modified fatty acid and
pan-PPAR agonist with high affinity towards PPARα. Hepatic gene expression of PPARα, PPARβ/δ
and the enzymes involved in the choline oxidation pathway were analyzed and concentrations
of metabolites were analyzed in plasma and urine. TTA treatment altered most biomarkers, and
the largest effect sizes were observed for plasma concentrations of dimethylglycine, nicotinamide,
methylnicotinamide, methylmalonic acid and pyridoxal, which were all higher in the TTA group
(all p < 0.01). Hepatic Pparα mRNA was increased after TTA treatment, but genes of the choline
oxidation pathway were not affected. Long-term TTA treatment was associated with pronounced
alterations on the plasma and urinary concentrations of metabolites related to one-carbon metabolism
and B-vitamin status in rats.
Keywords: dimethylglycine; methylmalonic acid; one-carbon metabolism; peroxisome
proliferator-activated receptors; tetradecylthioacetic acid
1. Introduction
Elevated plasma total homocysteine (tHcy) is related to increased risk of atherothrombotic
cardiovascular disease (CVD) [1]. However, lowering of tHcy with B-vitamins has not improved
prognosis among CVD patients [2], which is questioning a causal relationship and encourages
investigation into novel mechanisms associated with elevated plasma tHcy [3]. Circulating and
urinary concentrations of various metabolites along the choline oxidation pathway, which is linked to
remethylation of Hcy, have been related to major lifestyle diseases including CVD and diabetes [4–8].
We have recently shown that higher plasma dimethylglycine (DMG) concentrations are associated with
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increased risk of acute myocardial infarction as well as total and cardiovascular mortality, independent
of traditional risk markers including elevated plasma tHcy [6,7].
Homocysteine (Hcy) resides at a branch point of three metabolic pathways. Remethylation of
Hcy back to methionine is catalyzed either by the cobalamin-dependent methionine synthase (MS, EC
2.1.1.13) or betaine-homocysteine methyltransferase (BHMT, EC 2.1.1.5), using 5-methyltetrahydrofolate
(mTHF) or betaine as the methyl donor, respectively. Hcy catabolism to form cysteine is carried out by
the vitamin B6 dependent transsulfuration pathway [9] (Figure 1). Hcy metabolism is linked to the
choline oxidation pathway by BHMT, which demethylates betaine to form DMG [10]. DMG is further
oxidized to sarcosine and glycine by two mitochondrial flavoenzymes, i.e., DMG dehydrogenase
(DMGDH, EC 1.5.8.4) and sarcosine dehydrogenase (SARDH, EC 1.5.8.3) [11]. Interestingly, increased
flux through BHMT has also been associated with decreased DNA methylation of the promoter region
of the peroxisome proliferator-activated receptor (PPAR) α gene in mice, resulting in increased gene
expression of PPARα and its target genes [12]. In rats, activation of PPARα has been demonstrated
to reduce the genetic transcription of DMGDH, SARDH and glycine N-methyltransferase (GNMT,
EC 2.1.1.20), as well as both enzymes of the transsulfuration pathway [13]. This indicates a relationship
between PPARα and these pathways, and hence, we previously suggested that the association
between elevated plasma DMG and CVD risk may partly be related to enhanced endogenous PPARα
activity [6,7].
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towards PPARα [17], and we have previously demonstrated significant increases in PPARα target 
genes in the liver after TTA treatment, also accompanied by reduced plasma and hepatic lipid levels 
[18]. Although PPARα has been thoroughly explored according to its role in lipid and glucose 
metabolism, the relationship between PPARα and other metabolic pathways has only recently 
gained attention. Involvement in amino acid metabolism has been demonstrated [19,20], and fibrates, 
which are specific PPARα ligands have consistently been associated with elevated plasma tHcy [21], 
as well as being associated with elevated urinary output of choline, betaine and DMG [22,23], 
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PPARα is a key regulator of energy metabolism [14], with a large number of identified target
genes [15]. PPARα is activated by dietary or endogenous fatty acids and their derivatives [16].
Tetradecylthioacetic acid (TTA) is a sulfur-containing fatty acid analogue with a high affinity towards
PPARα [17], and we have previously demonstrated significant increases in PPARα target genes in
the liver after TTA treatment, also accompanied by reduced plasma and hepatic lipid levels [18].
Although PPARα has been thoroughly explored according to its role in lipid and glucose metabolism,
Nutrients 2016, 8, 26 3 of 13
the relationship between PPARα and other metabolic pathways has only recently gained attention.
Involvement in amino acid metabolism has been demonstrated [19,20], and fibrates, which are specific
PPARα ligands have consistently been associated with elevated plasma tHcy [21], as well as being
associated with elevated urinary output of choline, betaine and DMG [22,23], linking PPARα to
one-carbon metabolism. In terms of the choline oxidation pathway, PPARα activation has in rodent
models been associated with a reduction in Dmgdh and Sardh mRNA [13] and lower protein level of
SARDH [24], and recently, long-term TTA treatment was associated with lower protein expression of
BHMT, DMGDH and SARDH [25]. However, whether TTA treatment affects the related metabolites
has yet to be explored. Also, activation of PPARα has been shown to increase the synthesis of vitamin
B3 from tryptophan by regulating key enzymes in this pathway [26], but whether PPAR activation
influences the status of other B-vitamins is uncertain.
The aim of the current study was to investigate how PPAR activation by TTA supplementation
affected blood and urinary concentrations of components of the choline oxidation pathway and
one-carbon metabolites, as well as systemic markers of B-vitamin status.
2. Materials and Methods
2.1. Animals and Diets
Male Wistar rats (n = 20), 8–10 weeks old on arrival and weight 260–270 g (Taconic Europe A/S,
Lille Skensved, Denmark), were randomly allocated to receive either a high fat control diet (Control)
with 25% fat (23% lard, 2% soybean oil, weight/weight) or a high fat diet supplemented with TTA
(TTA) (22.6% lard, 2% soybean oil, 0.4% TTA, weight/weight). The diets had the same amounts of
micronutrients, and the rats had free access to water and feed during the study period. The animals
investigated were part of a larger study, and more detailed descriptions of this experiment and the
composition of the diets have previously been published [27]. Feed intake was comparable between
groups, but the TTA treated rats gained less weight as compared to Controls [28].
After 50 weeks, the animals were sacrificed under non-fasting conditions by anaesthetization
with Isofluorane (Forane, Abbott Laboratories, Abbott Park, IL, USA) inhalation. Blood was drawn by
cardiac puncture and collected in BD Vacutainer tubes containing EDTA (Becton-Dickinson, Plymouth,
UK). Urine was collected directly from the urinary bladder.
2.2. Ethics Statement
The animal experiments complied with the Guidelines for the Care and Use of Experimental
Animal use and the study protocols were approved by the Norwegian State Board for Biological
Experiments with Living animals (“Forsøksdyrutvalget”, permit number 2005140).
2.3. Biochemical Analyses
With the exception of plasma cobalamin, which was measured in only seven rats per group due
to limited amounts of plasma, all blood metabolites were analyzed in 10 rats per group. Urinary
metabolites were analyzed in 9 control animals and in 8 TTA treated rats. All analyses were performed
at Bevital A/S (Bevital, Bergen, Norway). In plasma, methylmalonic acid (MMA), tHcy, cystathionine,
serine and glycine were analyzed by gas chromatography coupled with tandem mass spectrometry
(GC-MS/MS) [29]. Plasma choline, betaine, DMG, methionine and cysteine, as well as all vitamin B2,
B3, and B6 forms and metabolites were analyzed by liquid chromatography coupled with tandem
mass spectrometry (LC-MS/MS) [30,31]. Plasma folate [32] and cobalamin [33] were measured by
microbiological assays. In urine, cysteine, cystathionine, sarcosine, glycine, serine and MMA were
measured by GC-MS/MS [29], and methionine, choline, betaine and DMG by LC-MS/MS [30].
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2.4. Gene Expression Analysis
RNA was purified from frozen liver samples and cDNA was produced as previously described [34].
Using probes and primers from Applied Biosystems (Foster City, CA, USA), real-time PCR was performed
with Sarstedt 384 well multiply-PCR Plates (Sarstedt Inc., Newton, NC, USA) on Ppara (Rn00566193),
Ppard (Rn 00565707), Bhmt (Rn00578255_m1), Dmgdh (Rn00594751), Sardh (Rn00454657_m1) and
Gnmt (Rn00567215_m1). Three reference genes were included: 18s (Kit-FAM-TAMRA (Reference
RT-CKFT-18s)) from Eurogentec (Seraing, Belgium), glyceraldehyde-3-phosphate dehydrogenase
(Gapdh, Mm99999915_g1) from Applied Biosystems, and ribosomal protein, large, P0 (Rplp0, Gene
ID 11837) from Thermo Fisher Scientific Inc. (Waltham, MA, USA). The absolute quantification was
normalized according to the reference genes as previously described [28], and the result is presented
normalized to 18s, which was selected by the NormFinder algorithm which ranks the candidate
reference genes according to their expression stability [35].
2.5. Statistical Analyses and Presentation of Data
The plasma concentrations of metabolites are presented as means (SD). Normality was assessed
by the Kolmogorov-Smirnov test, and the groups were compared with independent samples t-tests.
Standardized mean differences (SMD) (95% confidence interval) were calculated.
The concentrations of urinary metabolites were given as µmol of metabolite per mmol creatinine
(SD) to correct for dilution. We evaluated the relationship between plasma and urinary concentrations
of metabolites by calculating Pearson’s correlation coefficients.
Statistics were performed using IBM SPSS Statistics for Windows, version 21 (SPSS IBM.,
Chicago, IL, USA), Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) and Microsoft Excel
2010. p-values < 0.01 were considered statistical significant, according to the Benjamini and Hochberg
method of controlling the false discovery rate [36].
For the gene expression analyses, normality was analyzed by the D’Agostino and Pearson omnibus
normality test. The expression of Ppara, Bhmt, Dmgdh, Sardh and Gnmt mRNA was compared by t-test
while the expression of Ppard mRNA was compared by Mann-Whitney U test.
3. Results
Mean (SD) concentrations for all plasma and urinary metabolites and the SMD between groups
are presented in Figures 2 and 3. Compared to rats receiving the control diet, rats treated with TTA
differed in most metabolites and markers of B-vitamin status.
In terms of the transsulfuration pathway, higher concentration of plasma cystathionine was
observed (SMD = 1.56 [0.45–2.44], p = 0.004). Regarding components of the choline oxidation pathway,
rats in the TTA intervention group had higher concentrations of plasma DMG (SMD = 3.96 [2.39–5.49],
p < 0.001), glycine (SMD = 1.42 [0.41–2.39], p = 0.005) and serine (SMD = 1.51 [0.48–2.49], p = 0.003).
In urine, the TTA intervention group had higher concentrations of DMG (SMD = 1.69 [0.55–2.80],
p = 0.003).
Among B-vitamers and their respective metabolites, we observed higher concentrations of plasma
nicotinamide (NAM) (SMD = 6.06 [3.89–8.19], p < 0.001), N1-methylnicotinamide (mNAM) (SMD = 4.32
[2.16–6.45], p < 0.001) and pyridoxal (PL) (SMD = 3.38 [1.96–4.77], p < 0.001) in the TTA treated rats
as compared to controls, whereas plasma folate was lower (SMD = ´1.73 [´2.76–´0.68], p = 0.001).
Riboflavin (SMD = ´0.65, [´1.55–0.26], p = 0.13) and FMN (SMD = ´1.05 [´2.0–0.05], p = 0.039)
tended to be lower after TTA treatment. No difference was observed for plasma cobalamin, albeit both
plasma and urine concentrations of MMA were higher among TTA treated rats vs controls (SMD = 3.77
[2.0–5.51] and 2.05 [0.83–3.22], respectively, both p < 0.001).
As shown in Table 1, there were strong, positive correlations between plasma and urinary
concentrations for betaine (r = 0.62), DMG (r = 0.79) and MMA (r = 0.73), all p < 0.01.
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Table 1. Correlations between blood and urinary concentrations of metabolites. Male Wistar rats were
treated with either a low-fat control diet or a high-fat diet with or without additional TTA treatment,
n = 17. Pearson correlation coefficients were calculated between the plasma and urinary concentration
of metabolites.
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Nutrients 2016, 8, x 4 of 13 
 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh, Mm99999915_g1) from Applied Biosystems, 
and ribosomal protein, large, P0 (Rplp0, Gene ID 11837) from Thermo Fisher Scientific Inc. (Waltham, 
MA, USA). The absolute quantification was normalized according to the reference genes as 
previously described [28], and the result is presented normalized to 18s, which was selected by the 
NormFinder algorithm which ranks the candidate reference genes according to their expression 
stability [35]. 
2.5 Statistical Analyses and Presentation of Data 
The plasma concentrations of metabolites are presented as means (SD). Normality was assessed 
by the Kolmogorov-Smirnov test, and the groups were compared with independent samples t-tests. 
Standardized mean differences (SMD) (95% confidence interval) were calculated. 
The concentrations of urinary metabolites were given as µmol of metabolite per mmol 
creatinine (SD) to correct for dilution. We evaluated the relationship between plasma and urinary 
concentrations of metabolites by calculating Pearson’s correlation coefficients. 
Statistics were performed using IBM SPSS Statistics for Windows, version 21 (SPSS IBM., NY, 
USA), Prism 6.0 (GraphPad Software, Inc., CA, USA) and Microsoft Excel 2010. p-values < 0.01 were 
considered statistical significant, according to the Benjamini and Hochberg method of controlling 
the false discovery rate [36]. 
For the gene expression analyses, normality was analyzed by the D’Agostino and Pearson 
omnibus normality test. The expression of Ppara, Bhmt, Dmgdh, Sardh and Gnmt mRNA was 
compared by t-test while the expression of Ppard mRNA was compared by Mann-Whitney U test. 
3. Results 
Mean (SD) concentrations for all plasma and urinary metabolites and the SMD between groups 
are presented in Figures 2 and 3. Compared to rats receiving the control diet, rats treated with TTA 
differed in most metabolites and markers of B-vitamin status. 
 
Figure 2. Plasma concentrations of metabolites in rats receiving a high fat control diet or a high
fat diet with additional TTA treatment. Male Wistar rats were treated with a high-fat diet with
or without additional TTA treatment, n = 10 in each group. Mean (SD) plasma concentration of
the metabolites, as well as the standardized mean difference (95% CI) between the control and
the TTA treated animals. DMG indicates dimethylglycine; FMN, flavin mononucleotide; MMA,
methylmalonic acid; mNAM, N1-methylnicotinamide; NAM, nicotinamide; PA, pyridoxic acid; PL,
pyridoxal; PLP, pyridoxal-5’-phosphate; SMD, standardized mean difference; tHcy, total homocysteine;
TTA, tetradecylthioacetic acid.
Nutrients 2016, 8, 26 6 of 13
Nutrients 2016, 8, x 5 of 13 
 
Figure 2. Plasma concentrations of metabolites in rats receiving a high fat control diet or a high fat diet 
with additional TTA treatment. Male Wistar rats were treated with a high-fat diet with or without 
additional TTA treatment, n = 10 in each group. Mean (SD) plasma concentration of the metabolites, as 
well as the standardized mean difference (95% CI) between the control and the TTA treated animals. 
DMG indicates dimethylglycine; FMN, flavin mononucleotide; MMA, methylmalonic acid; mNAM, 
N1-methylnicotinamide; NAM, nicotinamide; PA, pyridoxic acid; PL, pyridoxal; PLP, 
pyridoxal-5’-phosphate; SMD, standardized mean difference; tHcy, total homocysteine; TTA, 
tetradecylthioacetic acid. 
 
Figure 3. Urinary concentrations of metabolites in rats receiving a high fat control diet or a high fat 
diet with additional TTA treatment. Male Wistar rats were treated with a high-fat diet with or 
without additional TTA treatment, n = 10 in each group. Mean (SD) urinary concentration of the 
metabolites, as well as the standardized mean difference (95% CI) between the control and the TTA 
treated animals. DMG indicates dimethylglycine; MMA, methylmalonic acid; SMD, standardized 
mean difference; tHcy, total homocysteine; TTA, tetradecylthioacetic acid. 
In terms of the transsulfuration pathway, higher concentration of plasma cystathionine was 
observed (SMD = 1.56 [0.45–2.44], p = 0.004). Regarding components of the choline oxidation 
pathway, rats in the TTA intervention group had higher concentrations of plasma DMG (SMD = 3.96 
[2.39–5.49], p < 0.001), glycine (SMD = 1.42 [0.41–2.39], p = 0.005) and serine (SMD = 1.51 [0.48–2.49],  
p = 0.003). In urine, the TTA intervention group had higher concentrations of DMG (SMD = 1.69 
[0.55–2.80], p = 0.003). 
Among B-vitamers and their respective metabolites, we observed higher concentrations of 
plasma nicotinamide (NAM) (SMD = 6.06 [3.89–8.19], p < 0.001), N1-methylnicotinamide (mNAM) 
(SMD = 4.32 [2.16–6.45], p < 0.001) and pyridoxal (PL) (SMD = 3.38 [1.96–4.77], p < 0.001) in the TTA 
treated rats as compared to controls, whereas plasma folate was lower (SMD = −1.73 [−2.76–−0.68], p 
= 0.001). Riboflavin (SMD = −0.65, [−1.55–0.26], p = 0.13) and FMN (SMD = −1.05 [−2.0–0.05], p = 0.039) 
tended to be lower after TTA treatment. No difference was observed for plasma cobalamin, albeit 
both plasma and urine concentrations of MMA were higher among TTA treated rats vs controls 
(SMD = 3.77 [2.0–5.51] and 2.05 [0.83–3.22], respectively, both p < 0.001). 
As shown in Table 1, there were strong, positive correlations between plasma and urinary 
concentrations for betaine (r = 0.62), DMG (r = 0.79) and MMA (r = 0.73), all p < 0.01. 
  
Figure 3. Urinary concentrations of metabolites in rats receiving a high fat control diet or a high fat
diet with additional TTA treatment. Male Wistar rats were treated with a high-fat diet with or without
additional TTA treatment, n = 10 in each group. Mean (SD) urinary concentration of the metabolites, as
well as the standardized mean difference (95% CI) between the control and the TTA treated animals.
DMG indicates dimethylglycine; MMA, methylmalonic acid; SMD, standardized mean difference; tHcy,
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The hepatic gene expression analyses showed no differen e in th expression of Bhmt (Figure 4A),
Dmgd (Figure 4B), Sardh (Figur 4C) o Gnmt (Figur 4D). However, P ara mRNA was increased
2.1-fold (p < 0.001) (Figure 4E) and Ppard mRNA was increased 1.5-fold (p < 0.001) (Figure 4F) in the
TTA group.
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Figure 4. Gene expression in liver of rats receiving a high fat control diet or a high fat diet with
additional TTA treatment. Male Wistar rats were treated with a high-fat diet with or without additional
TTA treatment, n = 10 in each group. RNA was purified from frozen liver samples, and gene expression
was quantified relative to a reference gene. The bars represent the relative gene expression of Bhmt (A);
Dmgdh (B); Sardh (C); Gnmt (D); Pparα (E); and Ppard (F) compared to the Control group. Group
differences are evaluated with t-test and Mann-Whitney U test, and * indicates p < 0.001. Bhmt indicates
betaine-homocysteine methyltransferase; Dmgdh, dimethylglycine dehydrogenase; Gnmt, glycine
N-methyltransferase; Ppar, peroxisome proliferator-activated receptor; Sardh, sarcosine dehydrogenase;
TTA, tetradecylthioacetic acid.
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4. Discussion
4.1. Principal Findings
This long-term, 50 weeks, animal study indicated that TTA treatment was associated with
pronounced effects on the hepatic gene expression of PPARα and PPARβ/δ and on circulating
concentrations of metabolites along the choline oxidation pathway and one-carbon metabolism as
well as markers of B-vitamin status. The largest effect sizes were observed for plasma concentrations
of DMG, NAM, mNAM, MMA and PL, which were all higher in the TTA group. Our results extend
on previous findings by demonstrating that PPARs may also affect the plasma concentrations of
metabolites in the choline oxidation and one-carbon metabolism pathways, as well as circulating levels
of closely related B-vitamins.
4.2. Possible Mechanisms
4.2.1. TTA Treatment and the Choline Oxidation Pathway
The particularly high concentration of DMG associated with TTA treatment, both in plasma and
in urine, could be explained by TTA induced alterations in DMG production, catabolism, urinary
excretion or a combination thereof. At least part of the association is probably explained by decreased
catabolism of both DMG and sarcosine, as supported by the lower protein levels of DMGDH and
SARDH previously reported in TTA-treated animals [25]. However, as the hepatic gene expression
of Dmgdh and Sardh was not different between groups, this could be related to post-transcriptional
regulation or other mechanisms such as limited availability of cofactors. Both DMGDH and SARDH
are flavoproteins [37], and lower circulating concentrations of vitamin B2 as observed in this study
may thus reduce DMG catabolism. Moreover, folate-dependent remethylation of Hcy by MS utilizes
mTHF, which is produced from methylenetetrahydrofolate by methylenetetrahydrofolate reductase
(MTHFR, EC 1.5.1.20), and the reaction depends on MS reductase (MSR, EC 1.16.1.8). Notably, both
MTHFR and MSR are flavoproteins [38,39]. Accordingly, we observed markedly lower levels of folate
in the TTA-treated rats, and as mTHF makes up the majority of circulating folate [40], this suggests
reduced MTHFR flux. Hence, reduced MS flux due to lower concentrations of mTHF, may lead to a
compensatory increase in BHMT-mediated remethylation, enhancing DMG production.
Data on systemic sarcosine may have shed further light on potential changes of metabolites
downstream of DMG. Unfortunately, we were not able to determine sarcosine in plasma due to
analytical interference from the EDTA in tubes used for blood sampling. However, urinary sarcosine
tended to be higher in the TTA treated rats, indicating an increased glomerular filtration or decreased
fractional tubular reabsorption secondary to a probable higher plasma concentration. This was further
supported by the strong correlations between plasma and urinary levels of the closely related
metabolites DMG and betaine. Sarcosine can be produced from glycine in the cell cytosol, via
GNMT. As PPARα activation is suggested to inhibit flux through GNMT [13,24], decreased cellular
sarcosine production from glycine may have contributed to the higher plasma concentrations of glycine
and serine observed among the TTA treated rats. In line with this, a recent study found increased
concentrations of glycine and serine after PPARα activation, and a metabolic tracer experiment revealed
that increased rate of appearance into plasma, not decreased clearance or catabolism, was the main
mechanism responsible for this observation [41].
There are several possible routes for glycine synthesis that may be affected by TTA. Increased
production from sarcosine via SARDH is unlikely, due to the known inhibitory effect of PPARα
activation on SARDH [13,25]. Moreover, glycine may be formed from serine, which can be derived
through glycolysis [42], but as the glycolytic pathway is known to be inhibited by PPARα activity [15]
this is also not a likely source. Another possible route of glycine synthesis is from threonine
catabolism [42], which should be further explored as the plasma threonine concentration has
previously been reported to be markedly higher among the TTA-treated rats [28]. Notably, both
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PPARα activation [43] and TTA treatment [28] are associated with increased synthesis of carnitine,
which plays an essential role in fatty acid metabolism [44]. Because the production of each molecule
of carnitine also yields one molecule of glycine [44], it is reasonable to suspect increased carnitine
synthesis being a contributor to the elevated glycine concentrations.
4.2.2. TTA Treatment and Vitamin B3
B3 vitamers are cofactors for a vast number of enzymatic redox reactions, such as the β-oxidation
of fatty acids and substrate oxidation in Krebs cycle [45], as well as in the synthesis of carnitine [46].
In one-carbon metabolism, vitamin B3 is used as a reducing agent for both MTHFR and MSR [38,39],
as well as in the conversion of choline to betaine [47]. The primary cofactor form of vitamin B3,
nicotinamide adenine dinucleotide (phosphate) (NAD[P]), is formed from NAM and NA, and in the
current study TTA treatment was associated with significantly higher concentration of NAM and
also its breakdown metabolite mNAM. PPARα activation by WY14,643 was previously suggested
to increase the production of NAM originating from the catabolism of tryptophan [13,26,48], and
accordingly, such treatment has consistently been associated with elevated urinary concentrations of
both NAM and mNAM [13,49,50]. Higher plasma NAM and mNAM observed in the TTA group may
thus be due to PPARα-induced increased production, and may be related to increased requirements
for vitamin B3 due to enhanced β-oxidation, a well-known PPARα effect [51].
4.2.3. TTA Treatment and Vitamin B6
The transsulfuration pathway is activated by oxidative stress [52], and systemic vitamin
B6 deficiency has previously been associated with both increased oxidative stress [53] and
inflammation [54]. Of the B6 vitamers, only PL differed significantly between groups, with higher
concentrations being observed in the TTA group. Although the most commonly used marker of
vitamin B6 status is pyridoxal-5’-phosphate (PLP), total plasma B6-aldehyde (PL+PLP) is suggested
as a direct measure of B6 status [55]. Higher B6-aldehyde, as indicated by the higher levels of PL,
may thus represent improved B6 status, which is associated with lower inflammation and oxidative
stress [53,54]. This is consistent with the anti-inflammatory and anti-oxidative effects previously seen
by PPARα activation [14,15] and TTA treatment [18,56]. Notably, it has been demonstrated in cell
studies that the gene expression of alkaline phosphatase (EC 3.1.3.1), the enzyme responsible for
conversion of PLP to PL in plasma, is upregulated after PPARα activation [57]. This may explain why
PL, and not PLP, was higher after TTA treatment. However, the production of PLP from pyridoxine
and pyridoxamine is catalyzed by the flavoprotein pyridoxamine-pyridoxine 5-phosphate oxidase,
and lower availability of vitamin B2 may limit PLP production via this route, possibly adding to the
explanation why PLP is not increased [58].
4.2.4. TTA Treatment and Vitamin B12 Status
In this study, higher concentrations of MMA were observed in both plasma and urine among
the TTA treated rats. Plasma cobalamin, however, was unaffected, indicating a metabolic cobalamin
deficiency not reflected by low circulating cobalamin levels. This is in accordance with the observation
that serum cobalamin is often poorly correlated with clinical signs and the functional markers
of B12 deficiency [59]. The intracellular processing of cobalamin is complex and involves several
enzymes which, to our knowledge, have not been evaluated as candidate PPARα targets. The protein
expression of methylmalonyl-CoA mutase (MUT, EC 5.4.99.2), which catalyzes the catabolism of
methylmalonyl-CoA in the mitochondria, was reported to be elevated after TTA treatment [25]. This is
not in agreement with the elevated plasma and urinary MMA observed in the present study, and may
be a compensatory up regulation due to other TTA-induced metabolic alterations upstream of the MUT
reaction. One potential mechanism could be inhibition of the methylmalonic aciduria combined with
homocystinuria type C (MMACHC) protein. MMACHC is a flavoprotein responsible for making free
cobalamin available for cofactor synthesis [60], and lower availability of vitamin B2 may thus reduce
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MMACHC function. Also, MMACHC is dependent on glutathione transferase activity [61], linking
cobalamin metabolism to the transsulfuration pathway, which is a substantial source of cysteine for
glutathione synthesis [62]. PPARα activation is known to inhibit the transcription of both enzymes in
the transsulfuration pathway [13,63]. Elevated plasma cystathionine, observed after TTA treatment,
has previously been associated with impaired transsulfuration due to B6-restriction [64]. However, B6
depletion was not followed by decreased glutathione synthesis, indicating that glutathione synthesis
might primarily be regulated by other mechanisms [52]. The anti-inflammatory and anti-oxidative
properties of TTA may result in decreased glutathione synthesis, which then might hamper MMACHC
function. Together, lower availability of B2 and glutathione might reduce MMACHC function, leading
to a functional cobalamin deficiency, a known effect of MMACHC defects [65]. In terms of MMA
synthesis, the precursor for methylmalonyl-CoA is propionyl-CoA, derived from the catabolism of
both odd-chained fatty acids and branched-chained amino acids. Increased oxidation of fatty acids is a
well-known PPARα-effect, and it has been suggested that the catabolism of branched-chained amino
acids is stimulated by PPARα activity [66], possibly facilitating increased MMA production.
4.3. Strengths and Limitations
The main strength of this study is its randomized and controlled long-term dietary intervention
design. Extrapolation of the results to humans may, however, not be straightforward, as PPARα
activation affects rodents differently and to a larger extent than humans [67,68]. We can also not exclude
the possibility of PPAR-independent effects of TTA treatment influencing the results, thus limiting the
interpretation of the observations simply being due to PPARα activation. The animals were sacrificed
under non-fasting condition, which can be regarded a limitation of the assessment of metabolites.
In humans, we have shown that DMG concentrations are higher among non-fasting individuals
as compared to those with fasting samples [6]. Furthermore, blood and urinary concentrations of
the various metabolites do not necessarily reflect their tissue concentrations, prompting careful
interpretation in terms of metabolic flux [69]. It should also be acknowledged that the different
B-vitamin cofactors are involved in a myriad of metabolic pathways not discussed herein, which could
be of clinical interest related to PPAR activity. In terms of genes, it should be regarded a limitation that
we only have analyzed the hepatic expression, and not the expression in other tissues which might
be different.
4.4. Clinical Application
The involvement of PPARs in nutrient metabolism is well established. Thus, information on
the activity of PPARs, and PPARα in particular, may be of future interest when considering tailored
treatment or nutritional advice to the individual person. Metabolomics has been proposed as an
important tool to understand PPARα function [50], and targeted metabolic profiling focusing on
one-carbon metabolites may provide valuable information regarding PPARα activity. DMG, MMA
and vitamin B3 metabolites could be promising targets for such metabolic profiling in humans.
5. Conclusions
We have demonstrated that long-term treatment with TTA is associated with altered plasma
and urinary concentrations of metabolites related to one-carbon metabolism and B-vitamin status
in rats. We did not observe any differences in the hepatic gene expression of genes related to the
choline oxidation pathway, but the expression of PPARα was increased. Our findings should motivate
further investigation into how these metabolic pathways are regulated, specifically by looking into the
suggested role of PPARα and explore whether these metabolites may reflect hepatic PPARα activity.
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